Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

October 6, 2016

New Prognosis Prediction Tool Suggested for Lymphoma, but Experts Call for More Evaluation

News

Measuring total metabolic tumor volume may improve the accuracy of prognosis prediction in follicular lymphoma patients, according to a study analyzing data from several clinical trials. But experts caution that the method ... Read more

September 27, 2016September 27, 2016

Factors Identify Likely Outcomes in Lymphoma Patients on Third-Line Treatment

News

Researchers identified prognostic factors in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplants before relapsing again — taking on, in this work, rarely ... Read more

August 18, 2016August 18, 2016

Gazyva Combination Effective Therapy for NHL Patients Refractory to Rituxan

News

Results from the Phase 3 GADOLIN trial reveal that combining Gazyva (obinutuzumab) with bendamustine (available as Bendeka and Treanda) in patients with indolent non-Hodgkin’s lymphoma who are not responding to ... Read more

August 12, 2016August 12, 2016

Lymphoma Risk in Rheumatoid Arthritis Not Linked to TNF Blocking Drugs

News

Rheumatoid arthritis patients treated with biological drugs against the immune factor TNF are not at greater risk of developing lymphoma than peers treated with other medications, according to a study ... Read more

July 13, 2016July 13, 2016

Prognosis of Primary Gastric Lymphomas May Be Predicted with Double-Protein, Study Finds

News

Attempting to identify molecular markers of primary gastric B-cell lymphoma, researchers in China found that so-called double-hit lymphoma is rare in these patients, while a double-protein appearance of tumors predicts ... Read more

July 8, 2016July 8, 2016

Survivial of Specific Follicular Lymphoma Patients Might Improve with Stem Cell Transplant

News

Autologous stem cell transplants could greatly increase survival chances in patients with follicular lymphoma who undergo histologic transformation and form an aggressive tumor after successful immuno-chemotherapy. These patients have increased disease progression ... Read more

June 28, 2016June 28, 2016

New Tool Helps Predict Lymphoma in Sjogren’s Syndrome Patients

News

Greek researchers have developed a tool for doctors to better score the risk of non-Hodgkin’s lymphoma in patients diagnosed with Sjogren’s syndrome. The early identification of high-risk patients could allow ... Read more

June 14, 2016June 14, 2016

New CAR T-Cell Lymphoma Therapy Aims to Kill Only Cancerous B-Cells

News

CAR T-cell therapies have revolutionized cancer treatment, but the method, used to target B-cell related cancers, has its drawbacks. Now, researchers have designed a new type of CAR cell that ... Read more

June 10, 2016June 10, 2016

Poor Prognosis of Chemotherapy-Resistant Lymphoma Underscores Urgent Need for New Therapies

News

California-based Kite Pharma recently announced results from a large analysis of outcomes from chemorefractory diffuse large B-cell lymphoma, showing that these chemotherapy-resistant patients typically have a poor prognosis, irrespective of disease ... Read more

May 25, 2016May 25, 2016

Idelalisib for Indolent Non-Hodgkin Lymphoma a Viable Option, Review Finds

News

In a comprehensive review of idelalisib (Zydelig) treatment for patients with indolent non-Hodgkin lymphoma, Hofstra University’s Jacqueline C Barrientos concluded that the drug is a promising option in patients who have already been ... Read more